Introduction
Multiple sclerosis (MS) is a leading cause of disability in young adults and affects over 2.5 million people worldwide (1, 2) . MS is an inflammatory demyelinating disease of the CNS mediated by autoreactive T cells (3) . In MS and in its animal model (experimental autoimmune encephalomyelitis; EAE), circulating immune cells access the CNS across the blood-brain barrier to cause inflammation, myelin destruction, and neuronal damage, all of which set the stage for the development of the clinical manifestations of this disabling/progressive disease. The pathology of MS includes the presence of multiple demyelinated plaques in the CNS, the presence of inflammatory immune cells in the brain, loss of oligodendrocytes, and axonal demyelination and degeneration.
Blood-brain barrier dysfunction is a hallmark of many CNS disorders, including MS (4, 5) . It consists of a complex multicellular structure composed of a highly specialized and tightly sealed monolayer of brain endothelial cells buttressed by pericytes in the basal membrane, perivascular macrophages, and astrocyte foot processes (4, 5) . The blood-brain barrier restricts the transfer of molecules to the CNS parenchyma, but when disrupted -for example due to inflammation or stroke -neuronal functions can be compromised (6) . Brain endothelial cells achieve their highly selective permeability through a junctional complex by using both tight junctions and adherens junctions. Tight junctions between endothelial cells are principally responsible for the barrier function. Under healthy conditions, CNS endothelial cells express low levels of leukocyte adhesion molecules, such as vascular cell adhesion molecule 1 (VCAM1) and intercellular adhesion molecules (ICAMs; ICAM1 and -2) but are expressed highly in the vasculature during EAE and MS to promote T cell influx into the brain parenchyma (7) . T cell/endothelial cell interactions are mediated by adhesion molecules and chemokines and their respective chemokine receptors (4) . Tight junction proteins (platelet endothelial cell adhesion molecule [PECAM] , junctional adhesion molecule [JAM],
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occludin, claudins, and cadherin) regulate paracellular flux and prevent molecules/cells from translocating across the blood-brain barrier (4) (5) (6) 8) . Integrin activation leads to enhanced affinity of the adhesion molecule for its endothelial blood-brain barrier ligands including VCAM1, ICAM1, and P-selectins to support lymphocyte exit from the blood flow by extravasating through the vascular endothelial cell wall, a process of transendothelial migration (4) (5) (6) .
The ER is an elaborate membrane system that houses a variety of cellular functions that are critical for the maintenance of cellular homeostasis; synthesis of membrane-associated, luminal, and secreted proteins; correct folding and posttranslational modification of proteins and glycoproteins; lipid and steroid synthesis; and Ca 2+ signaling and storage (9) (10) (11) . To perform these diverse functions, the ER engages a wide assortment of multifunctional integral membrane and luminal chaperones, including calnexin, an ER integral membrane protein (12) . This protein is involved in the folding and quality control of membrane-associated and secreted glycoproteins (10) . Elimination of calnexin function has diverse effects in different organisms. Calnexin deficiency is lethal in Schizosaccharomyces pombe but not in Saccharomyces cerevisiae, Dictyostelium (13) , or Caenorhabditis elegans (14) . Interestingly, the loss of calnexin affects phagocytosis in Dictyostelium (15) and endocytosis in mammalian cells (16) . Calnexin is highly expressed during the development of the nervous system (17, 18) , and in mice, calnexin deficiency causes a peripheral axonal dysmyelinating phenotype involving reduced peripheral nerve conduction velocities (18) (19) (20) .
What is the calnexin link between the immune system and the nervous system? To answer this question, we examined the involvement of calnexin in the pathogenesis of MS. In this study, we discovered that calnexin is highly abundant in the brains of MS patients, while deficiency of calnexin in mice confers resistance to EAE. Although MS is regarded as a progressive autoimmune disease of the CNS, we did not find evidence indicating that calnexin deficiency in mice causes impaired development or function of the immune system. In contrast, we observed that the loss of calnexin caused a defect in CNS endothelial cell function that resulted in resistance of the blood-brain barrier to circulating T cell infiltrations. These findings identify a link between calnexin expression in CNS endothelial cells and the pathogenic cascade that drives neuroinflammation and destruction of the myelin sheath seen in MS.
Results
Calnexin is upregulated in brain samples of MS patients. Clinical symptoms of MS result from axonal and neuronal dysfunction and injury in human brain tissue. MRI patient brain scans characteristically show white matter lesions on FLAIR and T2-weighted sequences ( Figure 1A ). Lesions often occur in the periventricular region and juxtacortical white matter, sites enriched with venules, where blood-brain barrier breakdown frequently occurs. We discovered a high abundance of calnexin immunoreactivity ( Figure 1B , left column) and immune cell infiltration ( Figure 1B , right column, Oil Red O-stained) in MS brain sections, including acute, subacute, and chronic demyelinating lesions, as well as normal-appearing white matter (NAWM). Calnexin abundance in acute and chronic lesions was greater compared with control, NAWM, and subacute brain lesion tissue. Flow cytometric analysis also revealed high abundance of calnexin in MS brain endothelial cells ( Figure 1C ) indicating that calnexin was expressed in human CNS endothelial cells. This was further supported by immunostaining of human brain microvascular capillaries in control (non-MS) tissue versus acute and chronic demyelinating lesions ( Figure 1C) .
Calnexin-deficient mice are resistant to induction of EAE. To test whether high abundance of calnexin is important to MS pathogenesis, we induced EAE in calnexin-deficient mice using myelin oligodendrocyte glycoprotein (MOG ) inoculation in complete Freund's adjuvant (CFA). Within the first 2 weeks of injection, the WT mice -as well as mice with only 1 functional calnexin allele (heterozygotes, Canx +/-) -developed typical neurobehavioral deficits associated with EAE induction (Figure 2A) . Surprisingly, calnexin-deficient mice (Canx -/-) exhibited no signs of EAE throughout the disease course (23 days) ( Figure  2A ). Consistent with these neurobehavioral features, histologic evaluation of the CNS tissue at 14 days after immunization revealed dramatic differences between calnexin-deficient animals and WT littermates ( Figure 2B and Figure 3 ). In the EAE WT animals, there was significant infiltration of leukocytes into the white matter of the spinal cord ( Figure 2B and Figure 3A) . In contrast, spinal cords from calnexin-deficient mice immunized with the MOG peptide showed no evidence of immune cell infiltration ( Figure 2B and Figure 3A ). Immunostaining of WT and calnexin-deficient lumbar spinal cord section for markers of T cells, macrophages, and microglia (CD3ε, GFAP, IBA-1, F4/80) also showed no evidence of infiltration of these cells in calnexin-deficient EAE mice ( Figure 3, A and B) . Next, we analyzed the abundance of tran-scripts encoding inflammation-specific genes in the spinal cords from control and EAE-induced mice (Figure 3C ). The mRNAs for T cell receptor CD3ε, early activation marker; CD69, marker of inflammation; macrophage/microglia activation marker F4/80; GFAP; and cytokines IL-17, IL-1β, IL-6, and GM-CSF were dramatically increased in WT mice with induced EAE ( Figure 3C ). In agreement with histological analysis ( Figure 2B and Figure 3A ) of CNS tissue from calnexin-deficient animals with induced EAE, there was no induction of mRNA encoding any of the tested inflammation markers ( Figure 3C ).
To test the specificity of calnexin in conferring resistance of the Canx -/-mice to the EAE induction, we generated Canx -/-mice reconstituted with a transgene (Tg-CanxFL) that directs the ubiquitous expression of the full-length calnexin protein. -TG-CanxFL to induction of EAE was similar to that observed in WT or heterozygote animals ( Figure 2A ). Taken together, these findings demonstrate that global deletion of the calnexin gene in mice was protective against development of EAE and was associated with the impaired transmigration of encephalitogenic lymphocytes into the CNS parenchyma of Canx -/-mice. Furthermore, resistance to EAE required calnexin absence because susceptibility to EAE was restored by expression of the recombinant full-length calnexin protein in calnexin-deficient mice.
Peripheral immune response was not affected by the loss of calnexin. Next, we asked whether calnexin deficiency impacted the development and function of the peripheral immune system and, hence, resistance of the calnexin-deficient mice to EAE induction. MS is an autoimmune disease in which antibodies and T cells targeting myelin antigens are present in the blood (21) . The induction of EAE by immunization of mice with MOG leads to the appearance of anti-MOG antibodies and encephalogenic T cells in blood from immunized mice upon onset of the disease (22) . Consequently, secreted anti-MOG antibodies and T cells are pathogenic and contribute to demyelinating EAE episodes. Sera from WT and Canx -/-mice treated Figure 6B ) and demonstrated that the absence of calnexin had no significant impact on the development of the immune system. Next, we inoculated WT and Canx fl/fl /Lck-Cre + mice with MOG . Like WT mice, Canx fl/fl /Lck-Cre + mice developed EAE symptoms ( Table 1 ), indicating that calnexin deficiency in T cells specifically did not interfere with the recruitment of encephalitogenic lymphocytes into the CNS and the induction of EAE.
Transendothelial migration of T cells across the brain endothelium was inhibited in the absence of calnexin.
A pivotal feature of MS pathogenesis is that proinflammatory T cells in the blood cross the blood-brain barrier, resulting in focal inflammation and demyelination. Thus, we asked if the function of the blood-brain barrier was altered in the absence of calnexin and whether this was responsible for protection of Canx -/-mice against EAE induction. To address this question, we used a mouse brain endothelial cell line, bEND.3 (28, 29) , which serves as a cell culture model for studies of the blood-brain barrier endothelium. First, we found that cytokine-stimulated bEND.3 CNS endothelial cells displayed an increased abundance of calnexin immunoreactivity ( Figure 7A ). This finding recapitulated our observations in human brain sections from MS patients (Figure 1 ) and supported the notion that calnexin expression might be increased in the blood-brain barrier endothelial cells of MOG -treated mice. Next, we used an in situ gene-editing technique to generate calnexin-deficient bEND. 
Discussion
As a molecular chaperone, calnexin has been implicated in immunity because of its capacity to regulate the folding and assembly of the MHC class I complex or folding of the T cell receptor (30) . During development, calnexin is highly expressed in the nervous system, and elimination of calnexin in mice results in peripheral axonal dysmyelination, resulting in reduced nerve conduction velocities (18) (19) (20) . These findings revealed that the protein is important for the development and function of the nervous system. Here, we discovered a high abundance of calnexin protein in the brains of MS patients, suggesting that increased ) in each section of white matter. Nonpaired 2-tailed Student's t test was used to determine statistical analysis. *P ≤ 0.02; **P ≤ 0.006; ***P ≤ 0.0006. (C) Spinal cord inflammation was assessed by quantitative PCR of inflammation markers. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. Data presented are mean ± SEM of 3 independent experiments, 3 mice per group. The means were compared using unpaired 2-tailed Student's t test.
calnexin expression contributes to the pathogenesis of MS. The relevance of CNS calnexin to the occurrence of MS is demonstrated by our finding that mice lacking calnexin become resistant to EAE, despite the appearance of anti-MOG antibodies in the blood of calnexin-deficient mice immunized with MOG peptide. Importantly, in MOG immunized calnexin-null mice without neurobehavioral deficits, circulating lymphocytes secreted proinflammatory cytokines but showed no signs of immune cell infiltration into the CNS or induction of transcripts encoding inflammatory genes within the CNS. The importance of calnexin in the susceptibility to inflammatory demyelination was demonstrated by transgene-directed reexpression of calnexin in Canx -/-mice. The seemingly paradoxical results of this study, demonstrating that calnexin deficiency leads to dysmyelination and impaired peripheral motor function (18) (19) (20) while conferring protection against inflammation of the CNS in response to induction of EAE, suggest that calnexin is important for myelin formation, but in EAE, an elevated abundance of calnexin is associated with the pathogenic cascade that eventually culminates in the progressive destruction of the myelin. + splenocytes from Canx -/-mice of or EAE Canx -/-mice secreting IL-17. **P ≤ 0.01, ***P ≤ 0.001; n = 3. The means were compared using unpaired 2-tailed Student's t test. See complete unedited blots in the supplemental material.
MS is classified as a chronic progressive autoimmune disease of the CNS in which proinflammatory T cells, sensitized to myelin proteins, cross the blood-brain barrier, resulting in inflammatory demyelination. EAE in mice, an established model of MS, is characterized by extensive infiltration of the CNS by inflammatory cells (22) . Initiation of EAE involves the activation of myelin-specific Th17 cells (22) . Th17 cells, which produce inflammatory cytokines, including IL-17, are critical mediators of tissue damage in EAE (22) . We found no difference in IL-17 secretion between T cells isolated from WT and Canx -/-mice immunized with MOG , ruling out any contribution of IL-17 in EAE protection seen in the calnexin-deficient mice. Importantly, mice with targeted inactivation of the calnexin gene in T cells offered no resistance to EAE, as these mice developed EAE to the same level of severity exhibited by WT mice with EAE. These findings indicated that the absence of calnexin did not affect activation and expansion of myelin-specific T cells in the periphery during EAE, despite the relative protection against EAE development in calnexin-deficient mice.
Since T cell-specific inactivation of calnexin did not recapitulate the resistance to EAE exhibited by mice with global calnexin deficiency, we examined the transmigration of T cells across the blood-brain barrier using bEND.3 cells as a model of brain endothelial cells (29) . Canx -/--bEND.3 cells showed normal responses to stimulation by cytokines with respect to upregulation of cell adhesion molecules but failed to support transendothelial migration of T cells. This finding demonstrates that blocking of T cell migration across the blood-brain barrier underlies the observed resistance of calnexin-deficient mice to EAE. Blockage of lymphocytes binding to brain endothelium and reduction of lymphocyte transendothelial migration into brain parenchyma has long been considered a target for MS therapeutics development (31, 32) . Several adhesion molecules have been implicated in the binding of lymphocytes to inflamed blood vessels in the brain of mice with EAE. Blockade of VCAM1 interaction with integrin α4 localized on the cell surface of lymphocytes reduces the clinical severity of EAE (32) and is the basis for MS therapy. Interestingly, antibodies inhibiting binding of leukocytes to other endothelial proteins, including ICAM1, do not influence lymphocyte binding to the blood-brain barrier (33) .
Cytokine-stimulated Canx -/--bEND.3 cells express increased levels of VCAM1, ICAM1, and tight junction proteins, yet transendothelial migration of T cells is effectively blocked to protect calnexin-deficient mice against EAE. Calnexin is a type 1 integral ER membrane protein with a large portion of the C-terminal domain oriented to the cytoplasm (34, 35) and interacting with cytoplasmic proteins, including UBC9 (SUMOylation E2 ligase) (36), protein tyrosine phosphatase 1B (36) , N-myristoyltransferase 1 (37) , and SGIP1 (16) . While screening for calnexin interacting partner proteins in the nervous system, we discovered that the fatty acid binding protein 5 (Fabp5), a member of a family of highly conserved cytoplasmic proteins that bind long-chain fatty acids and other hydrophobic ligands, binds to the cytoplasmic domain of calnexin (38) . It has been reported that a deficiency in Fabp5 also protects against EAE (39, 40) . It is tempting to speculate that the calnexin/Fabp5 complex is a component of neuroproteostasis and lipidostasis (41) . The dysregulation of calnexin/Fabp5 function may be a key event in the pathogenesis of MS and represents an important target for therapeutics development aimed at promoting favorable clinical outcomes for patients afflicted with MS.
Methods
Human CNS tissue and grading. Snap-frozen postmortem CNS tissue blocks were obtained from both normal (n = 10) and MS (n = 18) cases with varying degrees of lesion inflammation at autopsy, with donor or next-of-kin informed consent for tissue donation from the NeuroResource tissue bank. MS lesions were classified into acute, subacute, and chronic on the basis of the number and distribution of Oil Red O-positive macrophages, myelin loss, and the cellularity in the borders and parenchyma of lesions. Clinical data were collected as shown in Supplemental Table 1 (42) .
Mouse models. Calnexin-deficient mice were generated as previously described (18). To inactivate the (27) , were crossed with Lck-Cre + transgenic mice (C57BL/6), which express the Cre recombinase under the control of the T cell-specific Lck promoter (The Jackson Laboratory, B6.Cg-Tg[Lck-cre]548Jxm/J]. Presence of the flox and Cre recombinase alleles was confirmed by PCR analysis using the following set of DNA primers: 5′-GCTCTGGATGCCTTGGGATTTGATTTCC-3′; 5′-GGATTTAGTGGATATCCCCAG-TATGAGC-3′; Cre-F2, 5′-GCCAGCTAAACATGCTTCATC-3′; Cre-B2, 5′-ATTGCCCCTGTTTCAC-TATCC-3′. Mice used in the present study carried double-flox and single Cre recombinase alleles.
An expression vector designed for ubiquitous expression under the ROSA26 promoter was used to generate transgenic mice expressing full-length calnexin protein on a CD1 WT mouse background, designated Canx -/--TG-CanxFL. Transgene expression was determined by PCR using the following set of DNA primers: 2N forward, 5′-GGAGGAGCGCTTCCGGCCGACG-3′; 2N reverse, 5′-CCACCCTGA-CAGAGACCCTCTGTC-3′; 2C forward, 5′-CGGAGAATGGGAGGCTCCTCAGAT T-3′; 2C reverse, 5′-GCAAGAAAGCGAGCTTCTAGATGGCC-3′. Mice were bred by crossing CD1 WT mice expressing full-length calnexin transgene with WT C57BL/6 mice. To generate calnexin rescue mice, WT CD1/ C57BL6 mice expressing the transgene were crossed with calnexin-deficient mice, and the heterozygote progeny with the transgene were bred again with calnexin-deficient mice, producing animals with the transgene on a calnexin-deficient background. Multifiber motor and sensory conduction studies were carried out using previously published protocols (18) .
EAE induction. Adult mice were injected s.c. in each hind leg with 50 μg of MOG (Peptide Synthesis Facility, University of Alberta) emulsified in 100 μl CFA (MilliporeSigma). Animals received 0.3 μg/ml of pertussis toxin injected i.p. Injection of pertussis toxin (List Biological Laboratories) occurred on the day of induction with MOG , with subsequent infection 48 hours later. Control animals were immunized with CFA and PBS (1:1) and pertussis toxin, as above. Animals were assessed daily for EAE clinical symptoms. A scoring system from 0-5 for clinical assessment of EAE symptoms was used (https://hookelabs.com/services/cro/eae/MouseEAEscoring.html). EAE scores were obtained daily and were calculated for each mouse during the time course of the disease. Time course graphs represent daily mean maximal scores. Mean EAE data is shown as ± SEM.
Measurement of anti-MOG antibodies and cytokines in serum. Sera of control and EAE mice were collected Histochemistry. Mice were perfused with PBS, with the brain and spinal cord tissues fixed in 10% formalin and with paraffin-embedded sections stained with H&E. IHC staining of formalin-fixed, paraffin embedded lumbar section of spinal cords were deparaffinised and rehydrated using decreasing concentrations of ethanol. The slides were boiled in 0.01 M trisodium citrate buffer, pH 6, for 20 minutes followed by incubation with 0.3% hydrogen peroxide to block endogenous peroxidases. Sections were then preincubated with blocking buffer (LI-COR) for several hours to block nonspecific binding. To detect selected immune cells markers, sections were incubated overnight at 4°C with anti-CD3ε (Serotec, catalog MCA500GA), anti-F4/80 (Abcam, catalog AB6640), anti-IBA1 (Wako Pure Chemical Industries Ltd., catalog 019-19741), anti-GFAP (Dako, catalog M0761) antibodies at 1:100 dilution, followed by secondary biotinylated antibody, avidin-biotin-peroxidase complexes (Vector Laboratories) and 3,3′-diaminobenzidine tetrachloride (Vector Laboratories). For quantification, spinal cord sections were scanned and photographed using Axioskop2 (Carl Zeiss MicroImaging Inc.). For quantitative analysis, a number of cells positive for CD3ε, IBA-1, F4/80, and GFAP were determined in 3 standardized, randomly placed fields of view of 50 μm . Top and bottom oligos were prepared and ligated with the vector as described (43) . DH5α E. coli-competent cells were transformed with the ligation mixture. Colonies were picked, and DNA extraction was performed. Positive ligation was confirmed with DNA sequence analysis. bEND.3 cells at a confluency of 70%-90% were transfected using TurboFect Transfection reagent (Thermo Fisher Scientific). Transfection was performed according to manufacturer's recommended protocol designed for adherent cells. Pairs of sgRNAs were used to mediate effective gene disruption. Individual clones were isolated from the cell population transfected with sgRNAs and assayed by both PCR and immunoblot analysis, to confirm successful inactivation of the calnexin gene. For PCR analysis, genomic DNA from the modified region was amplified using primers outside of the sgRNAs binding sites: forward, 5′-GCCTTGG-GATTTGATTTCCT-3′; reverse, 5′-GATCTGCATCTGGCCT-3′. PCR product amplified from transfected bEND.3 cells reflected a deletion of 3,198 bp. To further confirm deletion of part of the calnexin gene, the amplicon was sequenced to reveal the exact sites of the deletion (Supplemental Figure 2) . Immunoblot analysis was carried out with anti-calnexin antibodies raised against a peptide derived from the C-terminal of calnexin (Assay Designs, SPA-860, synthetic peptide corresponding to last 19 C-terminal residues of amino acid sequence of calnexin [residues 575-593; NH 3 + -AEEDEI LNRSPRNRKP RRE-COO -]). Transendothelial migration analysis. WT or calnexin-deficient bEND.3 cells were plated onto 12-well plates and cultured for 24-48 hours until cells formed an intact monolayer. The endothelial cell monolayer was treated for 24 hours with IL-1β (10 ng/ml) (eBioscience, Affymetrix) or TNF-α (3 ng/ml) (Invitrogen), and IFN-γ (60 ng/ml) (eBioscience, Affymetrix) added to the culture media. For transmigration experiments, bEND.3 cells were plated onto transwell inserts (Corning, 5 μm). Primary cultures of WT mouse splenocytes were isolated. Briefly, spleens were carefully removed, sliced into small pieces and placed on a 70-μm cell strainer, and treated with RBC lysing buffer according to the protocol, with a cell suspension of 1 × 10 6 cells/ml in the final preparation. Cells were activated with plate-bound CD3 antibodies (5 μg/ ml eBioscience) and soluble CD28 antibodies (2 μg/ml eBioscience). On the day of the experiment, T cells were labeled with CFSE (Invitrogen) according to manufacturer's protocol. The CFSE-labeled cell suspension was added to the monolayer of bEND.3 cells and incubated for 3 hours. Next, fluorescently labeled leucocytes from the lower well were collected, washed 3 times with PBS, and counted using flow cytometry.
Flow cytometry. Flow cytometry analysis was carried out using BD FACSCanto flow cytometer (BD
